Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	18.77	9.27	6.34
Research & Development	63.62	30.62	31.31
Operating Expenses	82.39	39.89	37.66
Operating Income	-82.39	-39.89	-37.66
Interest Expense	-	-	-0.11
Interest & Investment Income	14.58	1.31	0
Other Non Operating Income (Expenses)	-	-13.41	-0.08
Pretax Income	-67.81	-51.98	-37.84
Income Tax Expense	0.19	0.01	0
Net Income	-68	-51.99	-37.85
Net Income to Common	-68	-51.99	-37.85
Shares Outstanding (Basic)	17	1	0
Shares Outstanding (Diluted)	17	1	0
Shares Change (YoY)	2796.96%	35.20%	-
EPS (Basic)	-4.05	-89.61	-88.20
EPS (Diluted)	-4.05	-89.61	-88.20
Free Cash Flow	-74.82	-46.21	-32.27
Free Cash Flow Per Share	-4.45	-79.66	-75.20
EBITDA	-82.33	-39.87	-37.65
D&A For EBITDA	0.06	0.02	0.01
EBIT	-82.39	-39.89	-37.66

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q